MA
ARQT icon

MYDA Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

MYDA Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100,000
Closed -$1.89M – 144
2025
Q3 		$1.89M Buy
+100,000
New +$1.58M 0.41% 66
2024
Q4 		– Sell
-50,000
Closed -$465K – 136
2024
Q3 		$465K Buy
+50,000
New +$493K 0.1% 113

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

MYDA Advisors's ARQT Position: Q2 2026 in Review

MYDA Advisors held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 240,000 shares worth $6.29M. The position accounts for 0.94% of the portfolio, ranked #23.

MYDA Advisors first reported a position in ARQT in Q4 2023 and has held it in 11 quarters since. The position peaked at $8.86M in Q3 2025. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • MYDA Advisors held 240,000 shares of Arcutis Biotherapeutics worth $6.29M as of Q2 2026.
  • MYDA Advisors left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
  • Arcutis Biotherapeutics made up 0.94% of MYDA Advisors's portfolio in Q2 2026, its #23 holding.
  • MYDA Advisors first reported a position in Arcutis Biotherapeutics in Q4 2023 and has held it in 11 quarters since.
  • MYDA Advisors's Arcutis Biotherapeutics position peaked at $8.86M in Q3 2025.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on MYDA Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.